U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07311330) titled 'Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction' on Nov. 19.
Brief Summary: This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction
Study Start Date: Jan. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Atherosclerotic Cardiovascular Disease (ASCVD)
Erectile Dysfunction
Intervention:
DRUG: YN001 20mg Dose + 5% glucose injection
The treamtment group was given YN001 20 mg, o...